Matthew Taylor, an analyst from Jefferies, maintained the Hold rating on Baxter International (BAX – Research Report). The associated price target is $38.00.
Matthew Taylor’s rating is based on a combination of factors, including Baxter International’s ongoing CEO search and its strategic focus on innovation and growth. The company is actively seeking a new CEO who aligns with its vision, which is crucial for its future direction. The search involves both internal and external candidates, indicating a thorough approach to leadership transition.
Additionally, Baxter International is experiencing growth in its infusion market, expecting to gain market share in the coming years. However, the company faces modest tariff risks, particularly from China, though these are not expected to have a significant impact. The company’s financial guidance for 2025 includes steady sales growth and operating margins, but the presence of low-margin transition items poses a challenge. These elements contribute to the Hold rating, reflecting a balanced view of potential growth and existing risks.